Jan 04, 2024 / 01:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by. Welcome and thank you for joining Inflarx's conference call to discuss the results announced today from the multiple ascending dose part of the Phase I study with INF904. (Operator Instructions) Please note that today's call is being recorded. (Operator Instructions) I would now like to turn the call over to Dr. Niels Riedemann, CEO and Founder of Inflarx. Niels, please go ahead.
Niels Riedemann Inflarx NV-CEO
Thank you so much, Lori. Welcome everyone to our today's conference call. We're really excited to host this call today. I'll be leading you through this calling at the beginning. And I will share the presentation with Dr. Pamela Chong, our Chief Medical Officer.
Before I introduce the team on the next couple of slides, please take note. We'll be making forward-looking statements. There's an important notice and disclaimer related to that. And we will also be talking about data proprietary other data. So please take note of that disclaimer.
Next slide, please. So as I mentioned
InflaRx NV Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
